<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519844</url>
  </required_header>
  <id_info>
    <org_study_id>GHLIQUID-1670</org_study_id>
    <secondary_id>2005-000318-11</secondary_id>
    <nct_id>NCT00519844</nct_id>
  </id_info>
  <brief_title>Growth Hormone Treatment in Children Born Small for Gestational Age: Assessment of Satisfaction</brief_title>
  <official_title>Assessment of Satisfaction With Growth Hormone Treatment in Children Born Small for Gestational Age: Benefits of Galenic Form of the Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to assess satisfaction with
      growth hormone treatment in children of both sexes born small for gestational age and who are
      receiving growth hormone treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Satisfaction/preference with the method of treatment assesses by means of a satisfaction questionnaire and a standard questionnaire of preference</measure>
    <time_frame>after 3 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical (adverse events)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological (fasting glucose, fasting insulin, liver enzymes)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of the treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Foetal Growth Problem</condition>
  <condition>Small for Gestational Age</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children treated for 3 years with MaxomatÂ® because of small for gestational age

          -  Postnatal growth failure by the age of 3 years or more

          -  No associated growth hormone deficiency

          -  Height growth velocity greater than 2 cm/yr over the 12 month period preceding the
             inclusion

          -  Bone age no more than 13 years for girls and no more than 15 years for boys

        Exclusion Criteria:

          -  Known, evolving tumour

          -  Hypertrophic cardiomyopathy

          -  Hypertension not controlled on maximum therapy

          -  Benign intracranial hypertension

          -  Known glucose intolerance or known diabetes mellitus

          -  Acute or active chronic hepatitis

          -  Chronic renal failure

          -  Chromosomal and/or genetic syndromes (other than Silver-Russell syndrome) or
             abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2007</study_first_submitted>
  <study_first_submitted_qc>August 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2007</study_first_posted>
  <last_update_submitted>November 11, 2015</last_update_submitted>
  <last_update_submitted_qc>November 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

